Home > Boards > US OTC > Biotechs > Vivos Inc. (RDGL)

FDA does not require pre-market approval for veterinary

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Paulness Member Profile
 
Followed By 64
Posts 9,993
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Amended Registration a Offering Under the Securities Act of 1933 (1-a/a) Edgar (US Regulatory) - 10/8/2019 5:25:19 PM
Amended Registration a Offering Under the Securities Act of 1933 (1-a/a) Edgar (US Regulatory) - 9/9/2019 11:58:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/13/2019 3:46:20 PM
Registration a Offering Under the Securities Act of 1933 (1-a) Edgar (US Regulatory) - 7/29/2019 11:45:35 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2019 1:27:29 PM
Amended Quarterly Report (10-q/a) Edgar (US Regulatory) - 6/24/2019 1:20:58 PM
Information Statement (definitive, Revised) (defr14c) Edgar (US Regulatory) - 5/22/2019 5:03:56 PM
Information Statement - All Other (definitive) (def 14c) Edgar (US Regulatory) - 5/16/2019 1:48:24 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/13/2019 4:17:48 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/6/2019 6:05:49 PM
Proxy Statement - Other Information (preliminary) (pre 14c) Edgar (US Regulatory) - 4/29/2019 6:16:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/2/2019 5:14:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/25/2019 1:29:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2019 5:22:33 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/12/2018 2:45:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2018 6:12:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/6/2018 6:10:34 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2018 12:49:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/13/2018 6:09:06 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/9/2018 2:31:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/30/2018 5:31:13 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 10/26/2018 6:08:23 AM
Paulness   Saturday, 07/20/19 11:21:39 PM
Re: None
Post # of 125139 
FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

IsoPet® for treating animals uses the same technology as RadioGel™ for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

The Company is also engaging the FDA for premarket clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist